VETOQUINOL Corporate brochure 2012 (year 2011)

FOCUS JUNE LAUNCH OF CIMALGEX ® , A NEW TREATMENT FOR PAIN AND INFLAMMATION IN DOGS of innovative medicines for the treatment of anti-inflammatory and auto-immune diseases. With the relief it offers to dogs and the satisfaction and security provided to vets and owners, Cimalgex ® is expected to be a resounding success, all the more so for being the object of the first EU marketing authorization obtained by Vétoquinol, which is now authorized to sell Cimalgex ® in all the member states of the European Union. Vétoquinol plans progressive launches of the drug in all the regions in which it operates. 02 03 02 > With Cimalgex ® , Vétoquinol showed its ability to innovate in one of its major strategic domains: pain and inflammation. Its optimized efficacy, scientifically proven tolerance and simplicity of use make Cimalgex ® one of the best forms of treatment against pain and inflammation associated with canine osteoarthritis and surgery. The product of Vétoquinol’s R&D department, Cimalgex ® is a new-generation NSAID* based on Cimicoxib, a molecule discovered by Palau Pharma, a company specializing in the conception and development FOCUS SEPTEMBER EUROPEAN LAUNCH OF FORCYL ® THIS NEW DRUG, BASED ON 16% CONCENTRATED MARBOFLOXACIN, ENABLES CATTLE RESPIRATORY INFECTIONS TO BE TREATED WITH A SINGLE INJECTION. Forcyl ® complies with the latest official requirements concerning the use of antibiotics in animal health, and its single injection procedure (SISAAB* concept) greatly simplifies the administration of the drug. Capitalizing on the know-how developed in the creation of the drug, Vétoquinol has already registered international patents for Forcyl ® and has obtained the requisite marketing authorizations in all European countries. ** SISAAB: Single Injection Short Acting AntiBiotic 03 > The Vétoquinol Group has established itself as a marbofloxacin world expert. It is the first veterinary pharmaceutical laboratory to have developed the use of this molecule for cattle, pigs and pets. The outstanding advantage of this drug is a single injection of a limited volume. This product is the fruit of Vétoquinol’s scientific expertise in the fields of pharmacology and pharmacodynamics, coupled with extensive work carried out by the Group’s R&D department. * Non-Steroidal Anti-Inflammatory Drug 13 2011 ACTIVITY REPORT